Remdesivir output to be ramped up as Covid-19 cases rise sharply

Zydus had recently also slashed prices of its remdesivir brand Remdac to Rs 899 per dose

Drug majors are stepping on the gas to produce more doses of key antiviral drug remdesivir as India witnesses a new peak in daily Covid-19 cases.

At least four companies — Hetero, Cadila Healthcare (Zydus Cadila), Mylan, and Cipla — confirmed to Busin­ess Standard that they are working to raise production of this drug soon.

Pankaj Patel, chairman of Zydus Cadila, said they were planning to double their production of remdesivir from 30,000 vials daily. “In the next few weeks, we will double the current production. We are making 30,000 vials daily now. The demand for the drug is on the rise